CIT can broadcast your seminar, conference or meeting live to a world-wide
audience over the Internet as a real-time streaming video. The event can
be recorded and made available for viewers to watch at their convenience
as an on-demand video or a downloadable podcast. CIT can also broadcast
NIH-only or HHS-only content.

Babies born before the 28th week of pregnancy—more than 30,000 per year in the United States—are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks’ gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.

(CIT): Babies born before the 28th week of pregnancy--more than 30,000 per year in the United States--are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks" gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.